576
Views
14
CrossRef citations to date
0
Altmetric
Review

Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders

, &
Pages 1061-1072 | Received 08 Nov 2019, Accepted 26 Mar 2020, Published online: 13 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Patrick Schindler, Orhan Aktas, Marius Ringelstein, Brigitte Wildemann, Sven Jarius, Friedemann Paul & Klemens Ruprecht. (2023) Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Review of Clinical Immunology 19:1, pages 71-91.
Read now

Articles from other publishers (13)

Hannah Nora Wolf, Veronika Ehinger, Larissa Guempelein, Pratiti Banerjee, Tania Kuempfel, Joachim Havla & Diana Pauly. (2023) NMOSD IgG Impact Retinal Cells in Murine Retinal Explants. Current Issues in Molecular Biology 45:9, pages 7319-7335.
Crossref
Shervin Gholizadeh, Alex Exuzides, Katelyn E. Lewis, Chella Palmer, Michael Waltz, John W. Rose, Anna Marie Jolley, Jacinta M. Behne, Megan K. Behne, Terrence F. Blaschke, Terry J. Smith, Jennifer Sinnott, Lawrence J. Cook, Michael R. Yeaman, Ines Aguerre, Lilyana Amezcua, Tanuja Chitnis, Jessica Coleman Lewis, Casey Engel, May H. Han, Eric C. Klawiter, Alexandra Kocsik, Mason Kruse-Hoyer, Libby Levine, Michael Levy, Melanie Marcille, Maureen A. Mealy, Stephanie Moore, Devin S. Mullin, Katherine E. Nelson, Kaho B. Onomichi, Sarah M. Planchon, Ana Pruitt, Pavle Repovic, Claire S. Riley, Zoe Rimler, Andrew W. Russo, Collin Tanchanco Ocampo & Anna J. Tomczak. (2022) Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort. Journal of Neurology 270:4, pages 2048-2058.
Crossref
Li Jiao & Shougang Guo. (2022) Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Frontiers in Immunology 13.
Crossref
Martin W. Hümmert, Louisa M. SchöppeJudith Bellmann-Strobl, Nadja SiebertFriedemann PaulAnkelien Duchow, Hannah PellkoferTania KümpfelJoachim Havla, Sven JariusBrigitte WildemannAchim Berthele, Florian Then BerghMarc PawlitzkiLuisa Klotz, Ingo Kleiter, Martin StangelStefan GingeleMartin S. WeberJuergen H. FaissRefik PulAnnette WalterUwe K. ZettlMakbule SenelJan-Patrick Stellmann, Vivien Häußler, Kerstin Hellwig, Ilya AyzenbergOrhan Aktas, Marius RingelsteinOlivia Schreiber-Katz & Corinna Trebst. (2022) Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease. Neurology 98:11.
Crossref
Ana M. Cabal-Herrera & Farrah J. Mateen. (2022) Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder. The Neurologist 27:1, pages 14-20.
Crossref
Tobias Zrzavy, Fritz Leutmezer, Paulus Rommer, Gabriel Bsteh, Barbara Kornek, Thomas Berger, Daniela Prayer, Majda Thurnher & Lukas Haider. (2022) Imaging features to distinguish AQP4-positive NMOSD and MS at disease onset: A retrospective analysis in a single-center cohort. European Journal of Radiology 146, pages 110063.
Crossref
Rui Li, Jingqi Wang, Cong Li, Xiangfu Liu, Muyang Chu, Yanyu Chang, Yuge Wang, Xia Wang, Boguang Yu, Li Ling, Hui Yang, Huan Yang, Xueqiang Hu & Wei Qiu. (2021) Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. Journal of Neuroimmunology 356, pages 577604.
Crossref
Jaya Sharma, M. Tariq Bhatti & Helen V. Danesh‐Meyer. (2021) Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro‐ophthalmic review . Clinical & Experimental Ophthalmology 49:2, pages 186-202.
Crossref
Ankelien Duchow & Judith Bellmann-Strobl. (2021) Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 11:1, pages 49-59.
Crossref
Marinos C. Dalakas, Harry Alexopoulos & Peter J. Spaeth. (2020) Complement in neurological disorders and emerging complement-targeted therapeutics. Nature Reviews Neurology 16:11, pages 601-617.
Crossref
Katrin Giglhuber & Achim Berthele. (2020) Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 12:14, pages 1053-1066.
Crossref
Susanna Asseyer, Graham Cooper & Friedemann Paul. (2020) Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Frontiers in Neurology 11.
Crossref
Joseph Kuchling & Friedemann Paul. (2020) Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.